Peter Lawson
Stock Analyst at Barclays
(1.32)
# 3,369
Out of 4,734 analysts
93
Total ratings
35.14%
Success rate
-10.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Maintains: Equal-Weight | $9 → $11 | $3.98 | +176.73% | 4 | Oct 30, 2024 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $25 → $29 | $14.03 | +106.70% | 6 | Oct 25, 2024 | |
| RVMD Revolution Medicines | Maintains: Overweight | $54 → $60 | $40.29 | +48.92% | 3 | Sep 27, 2024 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $14 → $17 | $4.46 | +281.17% | 5 | Sep 10, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $32 → $33 | $13.08 | +152.29% | 4 | Aug 15, 2024 | |
| IMCR Immunocore Holdings | Maintains: Overweight | $92 → $66 | $29.02 | +127.43% | 2 | Aug 9, 2024 | |
| MGNX MacroGenics | Maintains: Overweight | $9 → $8 | $3.00 | +166.67% | 8 | Jul 31, 2024 | |
| ARVN Arvinas | Maintains: Overweight | $60 → $48 | $18.05 | +165.93% | 6 | Jul 31, 2024 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $75 → $105 | $110.05 | -4.59% | 10 | Jul 29, 2024 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $20 → $31 | $19.14 | +61.96% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $10.14 | +67.65% | 3 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $2.85 | +356.14% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 | $36.20 | -30.94% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $2.40 | +275.00% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $22 | $5.91 | +272.25% | 5 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $63 | $34.63 | +81.92% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $10 | $1.27 | +687.40% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $2 → $1 | $0.58 | +72.44% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.05 | +376.19% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $8 | $0.66 | +1,111.94% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $13.34 | +124.89% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $0.84 | +316.67% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $136.67 | +167.07% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $32.42 | +41.89% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $28 | $19.24 | +45.53% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.89 | +3,263.23% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $1.22 | +3,588.52% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $40.53 | +11.03% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.15 | +5,986.96% | 1 | Jul 14, 2017 |
Biomea Fusion
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $9 → $11
Current: $3.98
Upside: +176.73%
Arcus Biosciences
Oct 25, 2024
Maintains: Overweight
Price Target: $25 → $29
Current: $14.03
Upside: +106.70%
Revolution Medicines
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $40.29
Upside: +48.92%
Relay Therapeutics
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $4.46
Upside: +281.17%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $13.08
Upside: +152.29%
Immunocore Holdings
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $29.02
Upside: +127.43%
MacroGenics
Jul 31, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $3.00
Upside: +166.67%
Arvinas
Jul 31, 2024
Maintains: Overweight
Price Target: $60 → $48
Current: $18.05
Upside: +165.93%
Blueprint Medicines
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $75 → $105
Current: $110.05
Upside: -4.59%
Nurix Therapeutics
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $19.14
Upside: +61.96%
Jun 7, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $10.14
Upside: +67.65%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $2.85
Upside: +356.14%
Apr 11, 2024
Downgrades: Equal-Weight
Price Target: $25
Current: $36.20
Upside: -30.94%
Mar 7, 2024
Maintains: Overweight
Price Target: $7 → $9
Current: $2.40
Upside: +275.00%
Feb 29, 2024
Maintains: Overweight
Price Target: $18 → $22
Current: $5.91
Upside: +272.25%
Feb 29, 2024
Maintains: Overweight
Price Target: $47 → $63
Current: $34.63
Upside: +81.92%
Feb 27, 2024
Maintains: Overweight
Price Target: $6 → $10
Current: $1.27
Upside: +687.40%
Aug 10, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $0.58
Upside: +72.44%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.05
Upside: +376.19%
Aug 5, 2022
Maintains: Overweight
Price Target: $14 → $8
Current: $0.66
Upside: +1,111.94%
Jul 28, 2022
Initiates: Overweight
Price Target: $30
Current: $13.34
Upside: +124.89%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $0.84
Upside: +316.67%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $136.67
Upside: +167.07%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $32.42
Upside: +41.89%
Mar 4, 2020
Initiates: Underweight
Price Target: $28
Current: $19.24
Upside: +45.53%
Mar 4, 2020
Initiates: Overweight
Price Target: $30
Current: $0.89
Upside: +3,263.23%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $1.22
Upside: +3,588.52%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $40.53
Upside: +11.03%
Jul 14, 2017
Initiates: Buy
Price Target: $70
Current: $1.15
Upside: +5,986.96%